• News Releases
  • Jan. 06, 2021 (PDF/84KB)Products
    Myovant Sciences Announces U.S. Availability of ORGOVYX for the Treatment of Advanced Prostate Cancer
  • Dec. 28, 2020 (PDF/113KB)Licensing
    Consolidated Subsidiary Myovant and Pfizer Enter Into Collaboration to Develop and Commercialize Relugolix
  • Dec. 28, 2020 (PDF/188KB)Finances
    Sumitomo Dainippon Pharma Concludes Positive Impact Finance Agreement with Sumitomo Mitsui Trust Bank
  • Dec. 25, 2020CSR
    Posted Video of ESG Meeting (Discussion with Investors) [Webcast]
  • Dec. 24, 2020 (PDF/93KB)Products
    Urovant Sciences Announces U.S. FDA Approval of GEMTESA (vibegron) 75 mg Tablets for the Treatment of Patients with Overactive Bladder (OAB)
  • more
  • RSS
Our Efforts Against the Novel Coronavirus Disease (COVID-19)

Other Notices

  • Nov. 20, 2020Others
    Posted Factbook 2020 ver.2
  • Sep. 30, 2020Others
    Posted Integrated Report 2020
  • Jun. 30, 2020Others
    Posted Factbook 2020
  • more
  • RSS

IR Library

  • Financial Results Summary
  • Presentation
  • Integrated Report
  • Fact Book
Our Efforts Against the Novel Coronavirus Disease (COVID-19)
  • Company Introduction Movie

    Company Introduction Movie

    Continuing to challenge ourselves to support a healthy future for people

  • Research and Development

    Research and Development

    Aiming to create innovative pharmaceutical products

  • CSR

    CSR

    Targeting sustainable growth

  • Overseas Local Subsidiaries

    Overseas Local Subsidiaries

    Leading our global expansion